Shareholders' Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Oct. 02, 2024	Apr. 22, 2024	Jan. 07, 2024	May 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2024	Aug. 31, 2024	May 01, 2024	Oct. 31, 2023
Purchase Agreement, Knopp Amendment
Nature of business [Line Items]
Common stock issued (shares)				1,872,874
Issuance of common shares, net of offering costs				$ 65,981
Pyramid Biosciences, Inc.
Nature of business [Line Items]
Upfront payment of common shares, shares (in shares)			255,794,000
Upfront payment of common shares, value			$ 10,894
Upfront payment of common shares, shares issued (in shares)								253,838,000
Research and development							$ 5,689
Common shares issuable (in shares)							98,129
Common shares issued (in shares)									97,387
Common Shares
Nature of business [Line Items]
Common stock issued (shares)					2,154,857	8,544,951
Issuance of common shares, net of offering costs					$ 76,361	$ 317,720
Number of shares sold in transaction (in shares)		6,451,220
Issuance price per share (in dollars per share)		$ 41.00
Proceeds from sale of stock		$ 247,830
Equity Distribution Agreement aggregate amount					$ 300,000			$ 300,000	$ 300,000	$ 300,000	$ 450,000		$ 150,000
Common Shares | Subsequent event
Nature of business [Line Items]
Number of shares sold in transaction (in shares)	6,052,631
Issuance price per share (in dollars per share)	$ 47.50
Proceeds from sale of stock	$ 269,935
Purchase Agreement, Knopp Amendment
Nature of business [Line Items]
Number of securities called by warrants (shares)												294,195
Exercise price of warrants (in dollars per share)												$ 67.98
Warrants, fair value disclosure												$ 3,340
Equity Distribution Agreement | Common Shares
Nature of business [Line Items]
Common stock issued (shares)										4,248,588
Proceeds from sale of stock										$ 146,250